Floatz logo

Axicabtagene Ciloleucel

Large B-Cell Lymphoma

Zhejiang Cancer HospitalCell therapyPhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
73/ 100

Competitive context

70 Active assets in the Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
M.D. Anderson Cancer Center
Phase 4BB
Etoposide
University of California, Davis
Phase 2/3BB
Adriamycin
Ruijin Hospital
Phase 3BB
Prednisone
Ruijin Hospital
Phase 3BB

View all 49 →

Same molecule, other indications

Axicabtagene Ciloleucel is also rated in:

diffuse large B-cell lymphomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
primary mediastinal large B-cell lymphomaActive
BB
Indicative · Phase 2
71 / 100
View asset →
high grade B-cell lymphomaActive
BB
Indicative · Phase 2
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →